Oruka Therapeutics, Inc.: 5%+ holders

As of November 9, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Oruka Therapeutics, Inc. The largest reported stake is Fairmount Funds Management LLC's, at 19.5%. 17 filings are on record since July 17, 2025 (Schedule 13D/A, July 1, 2026).

Fairmount Funds Management LLC also filed stake reports on 13 other companies ↓

Sell to companies like Oruka Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 4,556,952 · Sole dispositive: 0 · Shared dispositive: 4,556,952 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: RTW Investments, LP · Sole voting: 0 · Shared voting: 3,139,030 · Sole dispositive: 0 · Shared dispositive: 3,139,030 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: Viking Global Investors LP · Sole voting: 0 · Shared voting: 1,503,478 · Sole dispositive: 0 · Shared dispositive: 1,503,478 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-12 · Reporting person: Capital World Investors · Sole voting: 3,401,639 · Shared voting: 0 · Sole dispositive: 3,401,639 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-12
• Event date 2026-07-01 · Holder: Fairmount Funds Management LLC · Percent: 19.5% · Shares: 14,553,895 · SCHEDULE 13D/A

Oruka Therapeutics, Inc. has 17 Schedule 13D or 13G filings on record since 2025-07-17. 5 holders' latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Oruka Therapeutics, Inc. and the warning signs.

See Oruka Therapeutics, Inc.'s free Snapshot Watch Oruka Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Oruka Therapeutics, Inc. and the records around it.

Oruka Therapeutics, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
• VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
• Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)

Want the whole picture on Oruka Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Oruka Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Oruka Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   18 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Oruka Therapeutics, Inc. by CUSIP 687604108 and gives its principal executive office as 855 Oak Grove Avenue, Suite 100, Menlo Park, CA 94025 (SCHEDULE 13G/A, 2026-08-14).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G/A, 2026-08-14

The percentages set forth herein are based on 60,312,101 shares of Common Stock outstanding as of April 30, 2026, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "Commission") on May 13, 2026. VGI: 2.5% Opportunities Parent: 2.5% Opportunities GP: 1.5% Opportunities Portfolio GP: 1.5% VGOP: 1.5% VGOD GP: 1% VGOD Portfolio GP: 1% VGOD: 1% O.Viking Global Investors LP, SCHEDULE 13G/A, 2026-08-14

Source of funds (Item 3)

Item 3 of the Schedule 13D is hereby amended and supplemented as follows: On July 1, 2026, Fund II delivered to the Company a notice of conversion pursuant to Section 6.1 of the Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the "Certificate of Designation") to convert 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock, in accordance with the terms of the Certificate of Designation. The conversion was effected for no cash consideration pursuant to the Certificate of Designation.Fairmount Funds Management LLC, SCHEDULE 13D/A, 2026-07-01

Timeline

Swipe the table sideways to see every column.

Questions about who owns Oruka Therapeutics, Inc.

Who owns Oruka Therapeutics, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Oruka Therapeutics, Inc.: Fairmount Funds Management LLC (19.5%, Schedule 13D/A, filed 2026-07-01), Venrock Healthcare Capital Partners III, L.P. (7.4%, Schedule 13G/A, filed 2026-08-14), BlackRock, Inc. (6.6%, Schedule 13G, filed 2026-01-21), Capital World Investors (5.6%, Schedule 13G, filed 2026-08-12) and RTW Investments, LP (5.2%, Schedule 13G, filed 2026-08-14).

Who are the largest shareholders of Oruka Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Oruka Therapeutics, Inc. on this page are Fairmount Funds Management LLC (19.5%), Venrock Healthcare Capital Partners III, L.P. (7.4%) and BlackRock, Inc. (6.6%).

When did Fairmount Funds Management LLC buy into Oruka Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2025-09-19, reporting 19.99%; its latest, Schedule 13D/A filed 2026-07-01, reports 19.5%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Oruka Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Oruka Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Oruka Therapeutics, Inc. is mentioned again
• Find former Oruka Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes